Cargando…

Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene

Cystic fibrosis (CF) is caused by loss of function of the CFTR chloride channel. A substantial number of CF patients carry nonsense mutations in the CFTR gene. These patients cannot directly benefit from pharmacological correctors and potentiators that have been developed for other types of CFTR mut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Venturini, Arianna, Borrelli, Anna, Musante, Ilaria, Scudieri, Paolo, Capurro, Valeria, Renda, Mario, Pedemonte, Nicoletta, Galietta, Luis J. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584557/ https://www.ncbi.nlm.nih.gov/pubmed/34769402 http://dx.doi.org/10.3390/ijms222111972

Ejemplares similares

Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel
por: Renda, Mario, et al.
Publicado: (2023)

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
por: Capurro, Valeria, et al.
Publicado: (2021)

Pharmacological Correctors of Mutant CFTR Mistrafficking
por: Pedemonte, Nicoletta, et al.
Publicado: (2012)

The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism
por: Pesce, Emanuela, et al.
Publicado: (2018)

Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel
por: Pedemonte, Nicoletta, et al.
Publicado: (2020)

Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells
por: Scudieri, Paolo, et al.
Publicado: (2020)

WS07.06 CFTR impacts SARS-CoV-2 infection in cystic fibrosis
por: Bragonzi, A., et al.
Publicado: (2023)

The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
por: Sondo, Elvira, et al.
Publicado: (2022)

Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators
por: Terlizzi, Vito, et al.
Publicado: (2023)

Intermolecular Interactions in the TMEM16A Dimer Controlling Channel Activity
por: Scudieri, Paolo, et al.
Publicado: (2016)

Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
por: Borgo, Christian, et al.
Publicado: (2022)

Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
por: Spanò, Virginia, et al.
Publicado: (2021)

CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium
por: Braccia, Clarissa, et al.
Publicado: (2022)

Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
por: Armirotti, Andrea, et al.
Publicado: (2019)

Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs
por: Ko, Wooree, et al.
Publicado: (2022)

High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
por: Merkert, Sylvia, et al.
Publicado: (2019)

Recoding of Nonsense Mutation as a Pharmacological Strategy
por: Temaj, Gazmend, et al.
Publicado: (2023)

Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis
por: Sharma, Neeraj, et al.
Publicado: (2018)

Brain Organoids as Model Systems for Genetic Neurodevelopmental Disorders
por: Baldassari, Simona, et al.
Publicado: (2020)

Recent Strategic Advances in CFTR Drug Discovery: An Overview
por: Rusnati, Marco, et al.
Publicado: (2020)

Identification, Structure–Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators
por: Brindani, Nicoletta, et al.
Publicado: (2020)

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion
por: Sharma, Jyoti, et al.
Publicado: (2021)

Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside
por: Höpfner, Friederike, et al.
Publicado: (2022)

Pharmacological Responses of the G542X-CFTR to CFTR Modulators
por: Fang, Xinxiu, et al.
Publicado: (2022)

From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations
por: Veit, Gudio, et al.
Publicado: (2016)

Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes
por: Baldassarri, Margherita, et al.
Publicado: (2022)

CFTR mutations altering CFTR fragmentation
por: Tosoni, Kendra, et al.
Publicado: (2012)

Goblet Cell Hyperplasia Requires High Bicarbonate Transport To Support Mucin Release
por: Gorrieri, Giulia, et al.
Publicado: (2016)

CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway
por: Sanderlin, Edward J., et al.
Publicado: (2022)

Dual Activity of Aminoarylthiazoles on the Trafficking and Gating Defects of the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Caused by Cystic Fibrosis Mutations
por: Pedemonte, Nicoletta, et al.
Publicado: (2011)

Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough
por: Lee, Rhianna E., et al.
Publicado: (2022)

Functional and Pharmacological Characterization of the Rare CFTR Mutation W361R
por: Billet, Arnaud, et al.
Publicado: (2020)

A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay
por: Sharma, Jyoti, et al.
Publicado: (2020)

Pharmacological induction of translational readthrough of nonsense mutations in the retinoblastoma (RB1) gene
por: Palomar-Siles, Mireia, et al.
Publicado: (2023)

New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach
por: Righetti, Giada, et al.
Publicado: (2020)

Non-canonical translation start sites in the TMEM16A chloride channel()
por: Sondo, Elvira, et al.
Publicado: (2014)

Normal Calcium-Activated Anion Secretion in a Mouse Selectively Lacking TMEM16A in Intestinal Epithelium
por: Vega, Génesis, et al.
Publicado: (2019)

Corrigendum: Normal Calcium-Activated Anion Secretion in a Mouse Selectively Lacking TMEM16A in Intestinal Epithelium
por: Vega, Génesis, et al.
Publicado: (2019)

Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
por: Righetti, Giada, et al.
Publicado: (2020)

Novel SCN5A p.W697X Nonsense Mutation Segregation in a Family with Brugada Syndrome
por: Micaglio, Emanuele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v2lo8jtcnvmkns6fc7pskrsd8k